Suchergebnisse - "Statland, Jeffrey M"

PubPharm (122)

1

Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy : implications for clinical trial design and mechanisms of disease progression

enthalten in: Human molecular genetics | 2024

von Wong, C. | Friedman, S. | Snider, L. | +13

UpdateOf: bioRxiv. 2023 Feb 20;:. - PMID 36865168

2

Correction to : A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

enthalten in: Orphanet journal of rare diseases | 2024

von Attarian, S. | Young, P. | Brannagan, T. | +17

ErratumFor: Orphanet J Rare Dis. 2021 Oct 16;16(1):433. - PMID 34656144

3

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4) : a randomised, double-blind, placebo-controlled phase 2b trial

enthalten in: The Lancet. Neurology | 2024

von Tawil, R. | Wagner, K. | Hamel, J. | +36

4

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

enthalten in: Orphanet journal of rare diseases | 2024

von Attarian, S. | Young, P. | Brannagan, T. | +17

5

Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline

enthalten in: European journal of neurology | 2024

von Witzel, S. | Statland, J. | Steinacker, P. | +5

6

Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis—insights from a completed randomized controlled trial with rasagiline

enthalten in: European Journal of Neurology | 2024

von Witzel, S. | Statland, J. | Steinacker, P. | +5

7

Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin : The MGSCIg study

enthalten in: European journal of neurology | 2023

von Pasnoor, M. | Bril, V. | Levine, T. | +12

8

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1 : a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial

enthalten in: The Lancet. Neurology | 2023

von Thornton, C. | Moxley, R. | Eichinger, K. | +24

CommentIn: Lancet Neurol. 2023 Mar;22(3):191-192. - PMID 36804078

9

Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design

enthalten in: bioRxiv.org | 2023

von Wong, C. | Friedman, S. | Snider, L. | +13

10

Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle : implications for clinical trial design

enthalten in: bioRxiv : the preprint server for biology | 2023

von Wong, C. | Friedman, S. | Snider, L. | +13

UpdateIn: Hum Mol Genet. 2024 Jan 24;:. - PMID 38268317

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]